SCHEMBL3604493

SCHEMBL3604493

CC1Cc2cc(-c3csc(NC(=N)N)n3)ccc2N1C(=O)C1CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 7/20 0.52
TP53 P04637 2/20 0.52
ABL1 P00519 2/20 0.51
SMN1; SMN2 Q16637 8/20 0.51
MAPT P10636 5/20 0.51
HTT P42858 3/20 0.51
NPSR1 Q6W5P4 2/20 0.51
NR2F2 P24468 2/20 0.51
LMNA P02545 4/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 1/20 0.50
NTSR1 P30989 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TSHR P16473 1/20 0.49
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610538 0.89 ALDH1A1 (0.54) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3608764 0.89 ALDH1A1 (0.61) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3607158 0.82 RAB9A (0.75) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3598355 0.81 ALDH1A1 (0.69) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL27768288 0.78 ALDH1A1 (0.46) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3609848 0.75 RAB9A (0.59) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3602577 0.74 KLK7 (0.69) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL14433895 0.73 MAPT (0.63) NPC1RAB9AKMT2AALDH1A1TP53
SCHEMBL3603474 0.72 RAB9A (0.71) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL3604832 0.72 MAPT (0.78) NPC1RAB9AMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 NPC1 267/4885RAB9A 1024/4885MEN1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.